Oncotarget

Research Papers:

The role of BRCA status on prognosis in patients with triple-negative breast cancer

Yuxin Xie, Qiheng Gou, Qianqian Wang, Xiaorong Zhong and Hong Zheng _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:87151-87162. https://doi.org/10.18632/oncotarget.19895

Metrics: PDF 864 views  |   HTML 1909 views  |   ?  


Abstract

Yuxin Xie1,*, Qiheng Gou1,*, Qianqian Wang1,*, Xiaorong Zhong1 and Hong Zheng1

1Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China

*These authors have contributed equally to this work

Correspondence to:

Hong Zheng, email: hzheng@scu.edu.cn

Keywords: BRCA, triple-negative breast cancer, prognosis, meta-analysis

Received: October 05, 2016     Accepted: July 18, 2017     Published: August 03, 2017

ABSTRACT

Studies have showed that dysfunction in the breast cancer susceptibility gene (BRCA) is associated with triple-negative breast cancer (TNBC); however, its effect on patient survival remains controversial. We investigated the distribution of BRCA1/2 mutations in unselected Chinese patients with TNBC and explored their roles in prognosis. Then a systematic review and meta-analysis were performed to evaluate the prognostic role of BRCA dysfunction, including BRCA1/2 germline/somatic mutations, BRCA1 promoter methylation, and low BRCA1 protein expression in TNBC patients. Pooled hazard ratios with 95% confidence intervals were estimated to determine the association between BRCA dysfunction and survival. Our results showed a high frequency of BRCA1/2 mutations, especially germline BRCA1 variants, were associated with bilateral breast cancer. Although no correlations were found between BRCA1/2 mutations and recurrence-free survival (RFS) or overall survival (OS). In the meta-analysis, patients with BRCA1 promoter methylation showed poor OS. However, there was a favorable impact on disease free survival (DFS) for TNBC patients with BRCA1 promoter methylation when received adjuvant-chemotherapy. In conclusion, BRCA1/2 mutations were associated with bilateral breast cancer and BRCA1 promoter methylation may have a prognostic effect on TNBC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 19895